BrainsWay Ltd.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $10M normalized base FCF (blend of FY2025 actual $15.2M and TTM-Jun'26 $5.8M, smoothing working-capital timing); 20% FCF growth years 1-5, 10% years 6-10; 10% discount rate; 3% terminal growth; +$55.0M net cash (Jun 2026, $62.1M cash/investments less $7.1M debt); 40.13M shares outstanding. Figures are for BrainsWay Ltd's Nasdaq-listed ordinary shares, which BRSYF (legacy OTC quotation) is economically equivalent to 1:1.

Reasoning: BrainsWay is a profitable, growing commercial-stage medtech (Deep TMS neurostimulation devices) with real revenue, earnings, and positive free cash flow, so a standard FCF DCF grounded in its own financials fits better than any pipeline- or asset-based model.